# Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19

> **NCT04360096** · PHASE2,PHASE3 · TERMINATED · sponsor: **APR Applied Pharma Research s.a.** · enrollment: 144 (actual)

## Conditions studied

- SARS-CoV 2
- COVID
- ARDS
- ALI
- Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
- Dyspnea

## Interventions

- **DRUG:** ZYESAMI™ (aviptadil acetate)
- **DRUG:** Placebo
- **DEVICE:** Nebulized administration of ZYESAMI™ or Placebo

## Key facts

- **NCT ID:** NCT04360096
- **Lead sponsor:** APR Applied Pharma Research s.a.
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-02-15
- **Primary completion:** 2021-12-15
- **Final completion:** 2021-12-31
- **Target enrollment:** 144 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2023-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04360096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04360096, "Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04360096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*